

myNEO Therapeutics Partners with University of Liverpool for Personalised Therapeutic Cancer Vaccine Trial

Ghent, Belgium – January 22, 2025 – myNEO Therapeutics is pleased to announce a strategic partnership with the University of Liverpool to support a Phase 1 clinical trial aimed at developing a personalised therapeutic cancer vaccine for patients with Non-Small Cell Lung Cancer (NSCLC).

The trial, which will recruit 10 NSCLC patients, represents a significant step forward in the development of individualised cancer immunotherapies. myNEO Therapeutics will provide advanced neoantigen prediction capabilities to identify patient-specific targets, enabling the creation of a personalised vaccine tailored to each patient's unique tumour profile.

"Our collaboration with the University of Liverpool exemplifies our commitment to pioneering personalised medicine in oncology," said Cedric Bogaert, CEO of myNEO Therapeutics. "Using our proprietary ImmunoEngine technology, we aim to identify and prioritise neoantigens that are most likely to elicit a robust immune response, ultimately enhancing the effectiveness of the vaccine. It's humbling to see how our years of dedicated technology development are resulting in a broad clinical pipeline of both in-house and external developments, tackling numerous cancer indications in parallel."

myNEO's ImmunoEngine technology combines state-of-the-art AI algorithms, genomics, and bioinformatics to analyse tumour-specific mutations and predict the most promising neoantigens for targeting. This innovative approach is designed to activate the patient's immune system against cancer cells while minimizing the risk of off-target effects.

The University of Liverpool's planned trial marks a crucial development in the quest for new, personalised therapeutic options for NSCLC, the most common form of lung cancer. By focusing on individual patient profiles, this trial seeks to harness the potential of personalised vaccines to deliver more effective and tailored treatments for those affected by this challenging disease.

"We are excited to collaborate with myNEO Therapeutics on this personalised vaccine trial," said Prof. Christian Ottensmeier, Director of Clinical Research at The Clatterbridge Centre. "Their expertise in neoantigen prediction is vital to the development of a therapeutic vaccine that could significantly impact patient outcomes."

This partnership builds on myNEO Therapeutics' ongoing efforts to advance the field of cancer immunotherapy through innovative and personalised solutions. The company remains dedicated to leveraging its technology platform to support clinical trials and partnerships that drive forward the development of next-generation cancer treatments.

About myNEO Therapeutics

myNEO Therapeutics is a biopharmaceutical company focusing on the development of breakthrough therapeutic cancer vaccines by applying cutting-edge AI technology to identify and validate novel cancer targets. The company's discovery platform is empowered by proprietary data analysis tools that allow rapid screening of immuno-genomic information from cancer patients. By focusing on the complete genome of patients, myNEO Therapeutics is able to identify impactful tumour alterations and previously unknown neoantigen targets from the untapped "dark genome," from which it aims to develop novel cancer immunotherapies.

To date, myNEO Therapeutics has achieved several pivotal milestones in realizing its vision: advancing immune-oncology treatments for both personalised as well as off-the-shelf approaches towards the clinic, in a range of solid tumour indications. myNEO Therapeutics intends to build a broad portfolio of anti-cancer therapeutics, both through internal development as well as via strategic corporate partnerships.

myNEO Therapeutics was founded in 2018 by leading biotech entrepreneurs Cedric Bogaert, Professor Wim Van Criekinge, and Jan Van den Berghe. Mark Vaeck, founder, and former CEO of biopharmaceutical company Ablynx, recently took up the chairman board position, while Bert Coessens, founder of Cartagenia, is COO. To find out more about myNEO Therapeutics, please visit our website: www.myneotx.com

About Liverpool University

Founded in 1881 as the original 'red brick', the University of Liverpool is one of the UK's leading research-intensive higher education institutions with an annual turnover of £675.1 million, including an annual research income of £160.6 million.

Consistently ranked in the top 200 universities worldwide, we are a member of the prestigious Russell Group of the UK's leading research universities and have a global reach and influence that reflects our academic heritage as one of the country's largest civic institutions.

The latest UK rankings of circa 130 institutions have placed the University of Liverpool at 23rd (Times and Sunday Times Good University Guide 2025), 27th (2025 Guardian University Guide), 25th (Daily Mail University Guide 2025) and 19th (2025 Complete University Guide) nationally. To find out more about Liverpool University, please visit our website: <https://www.liverpool.ac.uk/>

Media Contact

Cedric Bogaert, CEO
myNEO Therapeutics
Ghent, Belgium
info[at]myneotx.com

Alison Cornmell, Media Relations Manager
University of Liverpool
Liverpool, UK
alison.cornmell[at]Liverpool.ac.uk